PRECEMTABART TOCENTECAN
UNII V97BV45YBZ

Substance Identification & Data

This profile provides standardized clinical and technical data for Precemtabart Tocentecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) V97BV45YBZ.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2873366-83-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

V97BV45YBZ

CAS Registry Number

2873366-83-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

PRECEMTABART TOCENTECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C189819

National Cancer Institute reference terminology for clinical and research data.

INN ID

13008

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

NO-145

Identifier assigned by the United States Adopted Names Council.

Substance Type

Precemtabart Tocentecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Precemtabart Tocentecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Precemtabart Tocentecan

Common Names & Synonyms

Immunoglobulin G1 [235-proline,236-valine,237-alanine,331-serine,332-serine,de-448-lysine], anti-(human carcinoembryonic antigen-related cell adhesion molecule 5) (human monoclonal MBE-748 γ1-chain), complex with human monoclonal MBE-748 κ-chain, dimer, 214′′,214′′′,222,222′,228,228′,231,231′-octakis[S-[1-[3-[[2-[[5-[[[[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]carbonyl]oxy]methyl]-2-(β-D-glucopyranuronosyloxy)phenyl]amino]-2-oxoethyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]-L-cysteine]

M 9140 [WHO-DD]

PRECEMTABART TOCENTECAN [USAN]

immunoglobulin G1-kappa, anti-[Homo sapiens CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e)], Homo sapiens monoclonal antibody, conjugated on an average of 8 cysteinyl residues to tocentecan, comprising a linker and a camptothecin derivative (exatecan); H-gamma1 heavy chain Homo sapiens (1-447) [VH (Homo sapiens IGHV4-31*02 (90.9%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [10.7.11] (26-35.53-59.98-108)) (1-119) -Homo sapiens IGHG1*03, G1m3, nG1m1 CH1 R120, CH3 E12, M14, G1v50 CH2 delE1.4, P1.3, V1.2, A1.1, G1v60 CH2 S115, S116 (CH1 R120 (216) (120-217), hinge 1-15 (218-232), CH2 E1.4>del, L1.3>P (235), L1.2>V (236), G1.1>A (237), A115>S (331), P116>S (332) (233-341), CH3 E12 (357), M14 (359) (342-446), CHS K2>del (447)) (120-447)], (222-214')-disulfide with L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-15*01 (94.7%) -IGKJ3*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1SV, glycoform alfa; substituted at the sulfur atoms of an average of 8 L-cysteinyl residues among 222, 228, 231, 214', 222'', 228'', 231'' and 214''' with radical group 1-{3-[(2-{5-[({[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]carbamoyl}oxy)methyl]-2-(β-D-glucopyranuronosyloxy)anilino}-2-oxoethyl)amino]-3-oxopropyl}-2,5-dioxopyrrolidin-3-yl (tocentecan)

precemtabart tocentecan [INN]